Printer Friendly

Beam Therapeutics signs exclusive cross-licence agreements with Bio Palette.

M2 EQUITYBITES-May 31, 2019-Beam Therapeutics signs exclusive cross-licence agreements with Bio Palette

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Biotechnology company Beam Therapeutics said on Thursday that it has formed an exclusive cross-licence agreement with Bio Palette, a Japanese biotechnology company, for base editing intellectual property.

Pursuant to the agreement, Bio Palette has provided Beam with an exclusive licence to develop Bio Palette's intellectual property in human therapeutics, with the exception of rights to microbiome related therapeutics in Asia, which are retained by Bio Palette.

Concurrently, Beam has granted Bio Palette with an exclusive licence to IP from its foundational licence agreements to develop microbiome-related therapeutics in Asia.

Beam intends to to leverage Bio Palette's experience and expertise in Japan, while Bio Palette will assist Beam in developing relationships in Japan, and advise on Beam's business development strategy in Japan.

This agreement includes an undisclosed upfront payment to Bio Palette from Beam, an equity position in Beam by Bio Palette, plus royalties from sales of commercialised products by Beam or Bio Palette to the other party.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Geographic Code:9JAPA
Date:May 31, 2019
Words:188
Previous Article:Spirit Of Texas Bancshares elects new director, re-elects 5 others to board.
Next Article:Ladder Capital declares dividend of USD0.34 per share for Q2 2019.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters